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Aims Guidelines concerning b-blocker treatment following acute myocardial infarction (AMI) are based on studies under-
taken before the implementation of reperfusion and secondary prevention therapies. We aimed to estimate the ef-
fect of oral b-blockers on mortality in contemporary post-AMI patients with low prevalence of heart failure and/or
reduced left ventricular ejection fraction.
...................................................................................................................................................................................................
Methods
and results
A random effects model was used to synthetize results of 16 observational studies published between 1 January
2000 and 30 October 2017. Publication bias was evaluated, and heterogeneity between studies examined by sub-
group and random effects meta-regression analyses considering patient-related and study-level variables. The
pooled estimate showed that b-blocker treatment [among 164 408 (86.8%) patients, with median follow-up time
of 2.7 years] was associated with a 26% reduction in all-cause mortality [rate ratio (RR) 0.74, 95% confidence inter-
val (CI) 0.64–0.85] with moderate heterogeneity (I2 = 67.4%). The patient-level variable mean age of the cohort
explained 31.5% of between study heterogeneity. There was presence of publication bias, or small study effect, and
when controlling for bias by the trim and fill simulation method, the effect disappeared (adjusted RR 0.90, 95% CI
0.77–1.04). Also, small study effect was demonstrated by a cumulative meta-analysis starting with the largest study
showing no effect, with increasing effect as the smaller studies were accumulated.
...................................................................................................................................................................................................
Conclusion Evidence from this study suggests that there is no association between b-blockers and all-cause mortality. A pos-
sible beneficial effect in AMI survivors needs to be tested by large randomized clinical trials.
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Introduction
Oral b-blockers have been a central component of secondary preven-
tion pharmacotherapy following acute myocardial infarction (AMI) ir-
respective of its severity for decades. Recent international guidelines
on the management of coronary disease, however, call into question
the efficacy of b-blockers.1–4 The foremost reason for this is because
studies of b-blockers among patients following AMI were conducted
prior to the implementation of acute coronary revascularization and
the use of modern secondary preventive treatments.
Moreover, landmark studies which established the rationale for
the routine use of long-term oral b-blockade after AMI were pub-
lished in the early 1980s.5,6 The only randomized large-scale b-block-
er trial conducted in patients following AMI in recent years,7 found
no prognostic benefit of early intravenous metoprolol followed by 4
weeks of oral treatment compared with placebo. A meta-analysis of
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randomized, controlled trials did not find a mortality effect associated
with b-blockers in studies from the reperfusion era, as opposed to a
significant reduction in mortality for studies published in the pre-
reperfusion era.8
The incidence of AMI remains high and many patients with AMI
who do not have reduced left ventricular systolic ejection fraction
(LVEF) and/or heart failure (HF) receive oral b-blockers. Whilst b-
blockers are considered relatively safe and inexpensive, they do have
well-known side effects, and adherence to other (potentially more ef-
ficacious) secondary preventive medications may wane as a result of
concomitant use of b-blockers.9 Given the absence of randomized
controlled trials to test the efficacy of b-blockers in contemporary
AMI patients without reduced left ventricular function or HF are lack-
ing, meta-analyses of population-based studies are potentially of value
for guiding b-blocker treatment in clinical practice.
We hypothesized that the survival benefit of b-blockers observed
in historical trials may not be present in the contemporary post-AMI
population. As such, we aimed to estimate the effect of oral b-block-
ers on mortality in patients with both ST-elevation myocardial infarc-
tion (STEMI) and non-STEMI (NSTEMI) where the majority of
patients did not have reduced LVEF and/or no clinical signs of HF.
Methods
The review protocol is registered at https://www.crd.york.ac.uk/PRO
SPERO/, ID: CRD42017079199.
Eligibility criteria
All study types and sizes published after 1 January 2000 concerning
patients following AMI were eligible for inclusion. Studies where none or
only a minority of patients had a history of HF, were in Killip class >_III or
had LVEF <40% at baseline, were included. It was anticipated that not all
studies would have complete data on these three categories reflecting
HF and/or left ventricular (LV) systolic dysfunction. Studies that did not
provide estimates between the b-blocker group and the no b-blocker
group were excluded.
Study selection and search
The literature search strategy is presented in Supplementary material on-
line, Tables S1 and S2. We searched the electronic bibliographic databases
Embase and Medline(r) for studies written in English from inception until
18 July 2017, with an additional search undertaken per 30 October 2017.
After removal of duplicate references, two members of the review team
undertook initial screening of article titles and abstracts. Potentially, rele-
vant articles were obtained in full-text and read independently by three
review team members. Conflicts were resolved by consensus. Reference
lists were scrutinized to identify articles not included in the original
search.
Quality assessment
The Newcastle–Ottawa Scale (NOS) for cohort studies10 was used to as-
sess the quality of the included studies according to (i) methods for study
participant selection, (ii) appropriate control for confounding (compar-
ability), and (iii) methods for assessing the outcome. We further assessed
the timing of the study (prospective vs. retrospective), and methods used
to control for confounding (propensity score analysis vs. multivariate
analysis).
Data abstraction
The primary endpoint considered was all-cause mortality.
Publication status, study design, patient-related characteristics, and
results were extracted on a standardized form according to an a priori
protocol. Investigators were contacted for additional data. Patient-
related variables were mean age of the cohort, frequency of male sex, dia-
betes mellitus, hypertension, smoking, previous myocardial infarction
(MI); treatment with acetylsalicylic acid (ASA), statins, angiotensin recep-
tor blockers (ARBs)/angiotensin-converting enzyme inhibitors (ACEI), in
addition to LVEF, Killip class, history of HF, STEMI/NSTEMI, and percu-
taneous coronary intervention (PCI).
Quantitative data synthesis
Statistical pooling
The method used to combine results from individual studies, was based
on the adjusted risk estimate and its 95% confidence intervals (CIs)
obtained from each study. To obtain summary measures, a random
effects model according to the DerSimonian Laird method11 was used
because of the heterogeneity among studies.
Sources of heterogeneity, evaluation and quantification
Statistical heterogeneity was assessed with the Cochran’s Q test and its
magnitude evaluated by the I2 statistics (I2 values of 25%, 50%, and 75% in-
dicate low, moderate, and high heterogeneity, respectively).12 A series of
sensitivity analyses were undertaken, including subgroup analyses and
meta-regression to investigate potential sources of heterogeneity in the
association between b-blocker treatment and mortality. Data were strati-
fied according to the following study level variables; prospective vs. retro-
spective study design, statistical methods used to control for confounding
(propensity score vs. multivariable analysis), and the following patient-
level variables; country (Asia vs. US/Europe), AMI type (STEMI vs. STEMI/
NSTEMI or unclear), and revascularization (only PCI treated patients vs.
mixed or unclear). Subgroup analyses were extended by a random-effect
meta-regression analysis that allowed the effect of the continuous covari-
ates to be investigated (such as in years; median follow-up time and mean
age, and in percent; LVEF, male sex, diabetes mellitus, hypertension, and
smoking) as well as the categorical covariates used in the subgroup ana-
lysis. Meta-regression was performed to explore the influence of each
covariate on the effect of b-blockers. If the covariate decreased the
between-study variance, the source of heterogeneity was considered im-
portant. The estimate of s2 in the presence of a covariate in comparison
to that when the covariate is omitted allowed the proportion of the het-
erogeneity variance explained by the covariate to be calculated.13
Finally, a sensitivity analysis was undertaken to investigate the influence
of each study by omitting each in turn from the meta-analysis and assess-
ing the degree to which the magnitude and significance of the exposure
effect changed.14
Evaluation of publication bias or small-study
effect
Publication bias is known to occur in meta-analyses, as studies that show
a statistically significant effect of treatment are more likely to be pub-
lished. Such selective publication of studies may lead to biased estimates
that appear to be precise in meta-analysis based on literature search. In
order to assess potential publication bias or small-study effect, we used
the funnel-plot, which is a good visual evaluation of sampling bias. Funnel
plot asymmetry raises the possibility of bias, and leads to a questioning of
the interpretation of the overall effect when studies are combined in a
meta-analysis. Sterne et al.15 have suggested that the funnel plot should
be seen as a generic means of examining small study effect, which is the
Effect of b-blockers on mortality after myocardial infarction 13
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..tendency for smaller studies in a meta-analysis to show larger treatment
effects. To avoid evaluating publication bias only according to visually
judgement, this was complemented by Egger’s test of asymmetry applied
on the funnel plot.16
We used the trim and fill simulation method to detect and control
for bias.17 In the presence of publication bias, the trim and fill method
could help reduce bias in pooled estimates. Even though the perform-
ance is not ideal, this method is a kind of sensitivity analysis to assess
the potential impact of missing studies. This then allows an adjusted
overall estimate with CI to be calculated. A test of the presence of
bias could be derived from this method based on the estimated num-
ber of missing studies. The estimated effect of the missing studies pro-
vides an indication of whether the imputed missing studies affect the
overall result of the meta-analysis.
We followed the PRISMA guidelines for meta-analyses and systematic
reviews of observational studies in reporting the present study.18 All stat-
istical analyses were performed with Stata version 15 (Stata Corporation,
College Station, TX, USA) or R Package-meta (Guido Schwarzer, R
News 2007).
Results
Study selection
After identifying 7529 references, 7499 were excluded due to irrele-
vant content and duplicate publications, leaving 30 potentially eligible
studies. Fourteen of these did not fulfil the inclusion criteria (see
Supplementary material online, Table S3) and 16 studies19–34 were
thus included in the meta-analysis (Figure 1). Additional data were
obtained for three studies.23,29,34
Study characteristics
Study characteristics are shown in Table 1. The pooled cohort
comprised 189 385 patients with AMI. The median age was 64.6 years
(range 57.7–68.6 years), 75% was men (range 69.0–81.8%), and me-
dian follow-up was 2.7 years (range 0.5–5.2 years). Of ten studies
providing information, median LVEF was 53.7% (range 48.9–60.4%).
Only four studies used a predefined LVEF cut-off value for inclusion,
being >40% in two studies31,33 and >_ 50% in two.26,29 Eleven studies
provided information about history of HF, with a median prevalence
of 1.8% (range 0–27.3%). Eight studies provided information about
Killip class <_2 with a median prevalence of 90.6% (range 85.3–100%).
On average, 30% of patients had diabetes, 52% hypertension, 6% pre-
vious MI, and 45% were smokers when included. Average percen-
tages for concomitant treatments were 94% with aspirin, 69% with
statins, and 64% with ARBs/ACEIs. Ten studies were on Asian popu-
lations, and six on North American or European populations.
In total, 86.8% (n= 164 408) of the pooled cohort received b-
blockers. Information about b-blocker type and dose was provided in
two studies,23,33 five studies reported only the type prescribed at hos-
pital discharge,24,26,28,30,32 and for the remaining nine studies no infor-
mation was provided (see Supplementary material online, Table S4 for
further information about study b-blocker types and doses). Follow-
up information concerning dose changes, discontinuation or new b-
blocker prescriptions was not available for any of the included studies.
Two studies22,25 included subpopulations with prior MI eligible for
inclusion in the meta-analysis. All studies were cohort by design, of
which 14 were retrospective. For 11 studies, confounding was con-
trolled for on multiple clinically relevant variables by propensity score
....................................................................................................................................................................................................................
Table 2 Subgroup analysis performed according to patient and study characteristics considered as potential sources
of heterogeneity for outcome all-cause mortality
Subdivision N RR (95% CI) RR51, Z P-value Variation in RR due
to heterogeneity, I2 (%)
All studies 16 0.74 (0.64–0.85) 4.20 <0.001 67.4
ST-elevation myocardial infarction
All patients 7 0.70 (0.52–0.93) 2.44 0.015 70.3
Mixed/unclear 9 0.78 (0.67–0.91) 3.16 0.002 61.9
PCI
All patients 10 0.68 (0.54–0.86) 3.29 0.001 65.9
Mixed/unclear 6 0.83 (0.71–0.97) 2.39 0.017 57.8
Follow-up by quartiles
0.5–1.5 years 4 0.64 (0.41–1.01) 1.90 0.057 82.0
1.5–2.7 years 4 0.85 (0.70–1.03) 1.67 0.095 19.9
2.7–3.8 years 4 0.75 (0.51–1.10) 1.48 0.138 68.6
3.8–5.2 years 4 0.68 (0.51–0.91) 2.64 0.008 61.3
Timing of the study
Prospective 2 0.65 (0.44–0.98) 2.08 0.038 0.0
Retrospective 14 0.75 (0.65–0.87) 3.86 <0.001 69.8
Control for confounding
Propensity score analysis 11 0.74 (0.62–0.78) 3.48 0.001 70.0
Multivariate analysis 5 0.74 (0.56–0.97) 2.19 0.029 61.4
CI, confidence interval; RR, rate ratio.
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..analysis, and multivariable analysis in five studies (see Supplementary
material online, Tables S5 and S6). The quality of studies according to
the NOS was excellent, with seven studies achieving 9/9 and nine
achieving 8/9 stars (see Supplementary material online, Table S7).
Quantitative data synthesis
The pooled estimate from the 16 studies (Figure 2) found that oral b-
blockers compared with no oral b-blockers were associated with a
26% reduction in the risk of all-cause mortality [rate ratio (RR) 0.74,
95% CI 0.64–0.85] with moderate between study heterogeneity
(I2 = 67.4%). The funnel plot visually showed the possibility of bias or
small-study effect (Figure 3) confirmed by the Egger’s test (P= 0.001).
The trim and fill simulation method suggested seven studies as miss-
ing, and the imputed point estimate was altered (adjusted RR 0.90,
95% CI 0.77–1.04). This indicates a change in magnitude and signifi-
cance of the pooled effect after correction for publication bias or
small-study effect. The cumulative meta-analysis starting with the
largest study showed no effect, with increasing effect as the smaller
studies were accumulated (Figure 4).
According to the pre-specified subgroup analysis (Table 2), the
stratified pooled meta-analyses demonstrated no substantial differen-
ces in effect of oral b-blockers on all-cause mortality.
We extended the analyses with meta-regression, and the results
are presented in Table 3. One covariate was associated with mortality
risk; the patient related variable ‘mean age of the cohort’ showing
decreasing effect of b-blockers on mortality with increasing age of
the patients accounting for 31.5% of between study heterogeneity.
Of note is that neither subtype of AMI, LVEF, history of HF, length of
follow-up, concomitant medical therapy, or ethnicity of the cohort
was significantly associated with mortality.
The robustness of the primary result obtained from the 16 studies
was supported in the influential analysis. When omitting one study at
a time from the meta-analysis a stable pooled estimate was shown
(see Supplementary material online, Table S8).
Discussion
This meta-analysis of 16 cohort studies comprising 189 385 patients
following AMI of whom only a minority had reduced LVEF and/or
Figure 1 Study selection depicted in a PRISMA flowchart. A flowchart of the different phases of the systematic review.
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..clinical HF found that the use of oral b-blockers was associated with
a reduction in the risk of all-cause mortality. However, publication
bias or small-study effect was found to influence the result with
diluted effect seen after correction of small-study effect.
Heterogeneity could be explained by the patient related variable
mean age of the cohort.
b-Blockers have long since been a pharmacotherapy for the man-
agement of AMI, but currently their role in the treatment of AMI
could be called into question. In the 1980’s, after a series of
randomized controlled trials showed improved outcomes and
reduced mortality, b-blockers were approved for the treatment of
AMI.5,6,35 However, these trials preceded the reperfusion era and
enrolled mainly patients with large infarcts and/or HF. Meta-analyses
of recent observational studies of the impact of b-blockers after AMI
on mortality suggest a beneficial effect.36,37 Misumida et al.36 included
six subgroups of patients with preserved LVEF, treated with primary
PCI for STEMI (n= 10 857). In this selected population, oral b-block-
ers compared with no oral b-blockers were associated with a 21%
reduction in all-cause mortality. Huang et al.37 included ten studies of
whom the majority had STEMI, and eight with early revascularization
to find that b-blockers were associated with a reduced risk of all-
cause mortality for all subgroups, except those with sample size
<_1000 and those with preserved LVEF. Our study contrasts from
Misumida et al. and Huang et al. by including larger studies, and with
both STEMI and NSTEMI patients. Therefore, as opposed to the two
other studies, this meta-analysis represents a more general post-AMI
population with both subtypes of MI where the majority of patients
are treated with an oral b-blocker, even in the absence of HF or
reduced LVEF.
Our results based upon the largest studies are further supported
by a recent registry study of 90 869 Medicare beneficiaries aged
>_65 years who had prescriptions for ACE-inhibitors, ARBs, b-block-
ers, or statins and survived AMI >_180 days.9 Only those patients who
were adherent to ACE-inhibitors/ARBs and statins had similar mor-
tality rates to those adherent to all therapies, including b-blockers—
suggesting limited additional mortality benefit from b-blockers. The
problem with non-adherence to a medication may have been an im-
portant confounder. If sicker patients discontinue a medication more
commonly than their healthy peers, the benefits of adherence to that
medication will be exaggerated. In contrast, the directionality of bias
may be the opposite for b-blockers. Those with disease progression
and recurrent events may be more adherent to their b-blockers,
whereas younger, healthier individuals may be more susceptible to
real or perceived b-blocker side effects, and thus less adherent.38
The use of b-blockers following AMI is based upon historical evi-
dence and nowadays applied to a different treatment and population
landscape. Moreover, international advances in the management of
AMI have resulted in a decline in deaths,39,40 and it is possible that in
this context b-blockers may have lost some of their effectiveness.
Limitations
The lack of international consensus about the effectiveness of b-
blockers following AMI among patients without HF is, in part, a reflec-
tion of the lack of contemporary randomized evidence.
Consequently, inferences are left to be drawn from observational
data, which have inherent bias. Beyond smaller cohort studies, which
(as seen in this study) may impact upon the direction of pooled esti-
mates, cohort studies of the effectiveness of pharmacotherapies are
....................................................................................................................................................................................................................
Table 3 Meta-regression model between risk of all-cause mortality and the different patient-and study-level variables
Covariates N Level b-Coefficient Standard error t P-value as2 bHeterogeneity (%)
None 16 — -0.3105 0.0794 -3.91 0.001 0.05396 —
ST-elevation myocardial infarction 16 1/0 -0.0649 0.1674 -0.39 0.704 0.05861 -8.63
PCI 16 1/0 -0.1325 0.1625 -0.82 0.429 0.05621 -4.16
Median follow-up time 16 Years 0.0064 0.0597 0.11 0.917 0.06240 -15.65
Mean left ventricular ejection fraction 10 Percent 0.0133 0.0379 0.35 0.734 0.08332 -18.63
Mean age of patients in the cohort 16 Years 0.0530 0.0245 2.16 0.049 0.03697 31.48
Frequency in cohort
Men 16 Percent -0.0130 0.0252 -0.52 0.614 0.06012 -11.42
Diabetes mellitus 16 Percent 0.0051 0.0094 0.54 0.596 0.06396 -18.53
Hypertension 16 Percent 0.0081 0.0050 1.63 0.125 0.05842 -8.27
Smokers 15 Percent -0.0052 0.0045 -1.15 0.270 0.06757 -11.18
Previous MI 13 Percent -0.0037 0.0184 -0.20 0.843 0.06657 -13.04
Heart failure 11 Percent 0.0109 0.0080 1.35 0.209 0.04209 -14.71
ASA 13 Percent -0.0077 0.0102 -0.76 0.463 0.04577 -12.21
Statin 15 Percent -0.0011 0.0039 -0.30 0.772 0.04979 -18.09
ARB/ACEi 15 Percent -0.0014 0.0029 -0.49 0.633 0.05040 -19.55
Country (Asia vs. USA/Europe) 16 1/0 -0.0789 0.1651 -0.48 0.640 0.05978 -10.79
Prospective timing of the study 16 1/0 -0.1415 0.2901 -0.49 0.633 0.05640 -4.52
Propensity score analysis 16 1/0 -0.0160 0.1778 -0.09 0.930 0.06191 -14.73
as2 = between study variance.
bThe heterogeneity accounted by the covariate included in the random effect meta-regression.
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weakened by selection and confounding bias as well as missing data.
Even though some of the studies included in our meta-analysis used
propensity score methods, residual confounding may remain at play.
Our investigation is further limited by publication bias, or small-
study effect, which may lead to biased estimates which appear
precise.13
Compromises were made in this meta-analysis regarding the
number of patients with HF in each study. A small percentage
of patients had a history of HF (albeit between 20% and 30%
in two studies), were in Killip class >_3 and were assumed to
have LVEF <40%. Based upon these, in part incomplete data,
we have not been able to express a more clear cut-off for
the definition of HF than the statement of a majority of
patients being without HF and/or LV systolic dysfunction. In
the meta-regression model presented in Table 3, neither a his-
tory of HF nor mean LVEF was significantly associated with
mortality.
We did not have information from the included studies about the
type, dose, persistence, and new prescription of b-blockers, which
may have skewed their impact on mortality. In the study of Puymirat
et al.33 neither type of b-blockers at discharge nor dose was related
to mortality after adjustment for age and GRACE score. Similar find-
ings were reported by Goldberger et al.41 who could not demon-
strate increased survival in patients treated with b-blockers in doses
approximating those used in prior randomized trials compared with
lower doses. The authors state, however, that an important caveat
for their findings is that they do not represent randomized clinical
trial results.
Figure 2 Forest plot for meta-analysis of 16 cohort studies comparing b-blocker therapy with no b-blocker in post-AMI patients on all-cause mor-
tality during follow-up. Weights are from random effects analysis. CI, confidence interval; ES, effect size.
Figure 3 Funnel plot of the 16 cohort studies included in the
meta-analysis. logrr, log rate ratio; se, standard error.
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Conclusions
The results from this meta-analysis of nearly 200 000 patients follow-
ing AMI of whom only a minority had reduced LVEF and/or clinical
signs of HF, provides evidence that the association between b-block-
ers and long-term survival is due to small study effect, and that there
might not be a significant reduction in the risk of all-cause mortality
when controlling for bias. To be conclusive as for the efficacy of b-
blockers on mortality in patients without HF following AMI,
randomized controlled trials are a necessary next step.
Supplementary material
Supplementary material is available at European Heart Journal –
Cardiovascular Pharmacotherapy online.
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